DRUGMAKER
Adcock Ingram to shift product mix to protect its profit margins
Changes in consumer behaviour continue to put pressure on the group, but it has proceeded with an interim dividend and is looking to grow
24 February 2021 - 13:46
Adcock Ingram, which counts Panado painkillers and the cold and flu product Corenza C among its brands, plans to bulk up its range of consumer goods products to reduce its dependence on price-regulated medications as it battles the fallout from Covid-19
Acquisitions in the consumer goods space helped the drugmaker grow its turnover in the six months to end-December 2020, though profits fell. CEO Andy Hall said Adcock still has some gaps to fill in terms of personal care and baby products...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.